How to access Fintepla from Saudi Arabia, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi Arabia family of a child with Dravet syndrome or Lennox-Gastaut syndrome (LGS) may receive a prescription for Fintepla (fenfluramine oral solution) from their treating paediatric neurologist. Fintepla is FDA-approved, manufactured by UCB (following Zogenix), and is indicated for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged 2 years and older. Dravet syndrome is a severe developmental and epileptic encephalopathy typically driven by SCN1A pathogenic variants, while LGS is a severe childhood-onset epilepsy syndrome with a heterogeneous aetiology. In Saudi Arabia, Fintepla is not locally registered, which is why your paediatric neurologist will navigate the Saudi Food and Drug Authority (SFDA) named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Fintepla is an oral solution taken twice daily, dosed by weight and titrated over several weeks. Eligibility for the Dravet indication is based on clinical diagnosis (often supported by SCN1A genetic confirmation); for LGS, diagnosis is made on clinical and EEG criteria. Fintepla carries a risk of valvular heart disease and pulmonary arterial hypertension and is supplied via a Risk Evaluation and Mitigation Strategy (REMS) programme in the US, which includes mandatory baseline and periodic echocardiogram surveillance. Treatment requires a paediatric neurologist familiar with developmental and epileptic encephalopathies, with ongoing seizure diary tracking and paediatric-cardiology echocardiogram coordination. Because Fintepla is oral, in-country administration is straightforward once the prescribing plan and echocardiogram-surveillance arrangement are in place.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Fintepla legally importable into Saudi Arabia?
Yes, through the SFDA named-patient import framework, administered in coordination with the Ministry of Health for patients treated in public tertiary centres.
The named-patient mechanism allows a Saudi Arabia-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is available, (c) the physician takes clinical responsibility, and (d) chain of custody is documented end to end. Given the REMS-equivalent cardiac-surveillance requirement, the physician's plan must include a Saudi Arabia-based paediatric-cardiology arrangement for baseline and periodic echocardiograms.
How the pathway works, step by step
- Consultation with your paediatric neurologist. Clinical diagnosis of Dravet syndrome or LGS, with genetic testing where relevant (SCN1A for Dravet), seizure history, and current antiseizure regimen documented.
- Baseline cardiac assessment. A Saudi Arabia-based paediatric cardiologist performs a baseline echocardiogram before initiation and documents the surveillance schedule.
- SFDA named-patient application. Your physician or the hospital pharmacy files the application with clinical rationale, cardiac-surveillance plan, patient reference, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Fintepla from UCB's authorised distribution channel.
- Shipment. Fintepla ships with chain-of-custody documentation to the treating hospital pharmacy.
- Arrival, dispensing, and cardiac surveillance. The hospital pharmacy releases the bottle with dosing and titration instructions; paediatric cardiology schedules follow-up echocardiograms per the surveillance plan.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming Dravet syndrome or LGS diagnosis, supporting genetic/EEG evidence, baseline seizure profile, current antiseizure regimen, and Fintepla as the indicated treatment
- Verification of their Saudi Arabia medical licence (SCFHS / MOH)
- A copy of the genetic and/or EEG diagnostic report
- A paediatric-cardiology echocardiogram-surveillance plan with named cardiologist and cadence
- Patient identifier (anonymised reference where possible)
- An administration and monitoring plan including weight-based dosing, titration schedule, and seizure-diary cadence
Reserve Meds provides a physician documentation kit that bundles the templates SFDA reviewers expect to see for rare-paediatric-neurology named-patient imports, with particular attention to the cardiac-surveillance documentation central to Fintepla safety.
Costs and timing
Fintepla is weight-dependent in dosing, so annual cost scales with the child's body weight. Indicative 2026 US cash-pay annual cost sits in a broad range of roughly USD 100,000-200,000 depending on weight. International logistics, SFDA documentation handling, cardiac-surveillance coordination, and concierge fees add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing for first dispense after cohort intake opens is 7-14 days from the moment a complete SFDA application is submitted and the baseline echocardiogram is documented. Refills ship on a rolling basis against the monthly dispensing schedule and align with the echocardiogram-surveillance calendar.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: severe childhood epilepsies in Saudi Arabia families are often part of a longer diagnostic odyssey, with multiple hospital visits and regimen trials before a diagnosis of Dravet or LGS is settled. Our concierge coordination recognises the emotional toll that long journey exacts. We work with a single designated family case lead, often a mother supported by the father and grandparents, and align refill logistics with school terms, Hajj, Ramadan, and follow-up echocardiogram cadence.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Fintepla specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for SFDA review, including the cardiac-surveillance plan required for Fintepla.
- Logistics. Chain-of-custody shipment coordination to your prescribing hospital pharmacy, aligned with echocardiogram cadence.
- Concierge case lead. A named point of contact for the family, coordinating long-term refills, weight-based dose adjustments, and cardiac-surveillance diarising.
What we do not do: we are not the prescriber, we do not practise medicine, we are not the dispensing pharmacy, and we do not perform echocardiograms. All clinical decisions remain with your treating paediatric neurologist and paediatric cardiologist.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation including the cardiac-surveillance plan. See our trust and compliance page.
Is Fintepla a cure? No. Fintepla reduces seizure frequency in Dravet syndrome and LGS. Pivotal study data show meaningful reductions in convulsive seizure frequency for many patients. Your paediatric neurologist will discuss realistic outcome expectations.
What is the cardiac-surveillance requirement? Fintepla carries risk of valvular heart disease and pulmonary arterial hypertension, so baseline and periodic echocardiograms are mandatory. Your paediatric cardiologist manages the cadence.
Does Fintepla replace existing antiseizure medications? Typically no, Fintepla is added to an existing regimen under specialist supervision, with adjustment of other agents as the neurologist decides.
Will insurance or MoH coverage apply? Cash-pay is the default. Some Saudi Arabia patients may receive partial MoH or private-insurance consideration on a case-by-case basis; we supply documentation for submission but do not process claims directly.
Next step
For Fintepla coordination in Saudi Arabia, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.
Composite case examples. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.
Regulatory status of Fintepla (fenfluramine) in Saudi Arabia, 2026
Fintepla (fenfluramine) is approved by the US Food and Drug Administration for the labelled indication of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years and older (see the FDA approval record at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu). For a Saudi Arabia-based patient, the access pathway runs through the Saudi Food and Drug Authority (SFDA) framework. The official regulator portal is at www.sfda.gov.sa/en; the locally registered medicines list is at www.sfda.gov.sa/en/drugs-list.
Where Fintepla (fenfluramine) is held on the locally registered list at the time the case opens, standard prescription and in-country dispensing applies and the treating consultant at the prescribing tertiary centre coordinates supply through the institutional pharmacy. Where Fintepla (fenfluramine) is not yet on the locally registered list at the time the case opens, the named-patient and personal-import framework that the Saudi Food and Drug Authority (SFDA) maintains for reference-authority-approved medicines is the operative route. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies), no locally available alternative is clinically equivalent for the specific patient indication, the treating physician of record takes documented clinical responsibility, and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility. Confirm current registration status at intake; the published registration list governs.
Tertiary centers and clinical coordination in Saudi Arabia
The Saudi Arabia tertiary referral network for a Fintepla (fenfluramine) case is concentrated at King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh and Jeddah, King Abdulaziz Medical City (KAMC), King Fahad Medical City (KFMC), Princess Noorah Oncology Center, and King Fahd Specialist Hospital Dammam. These centers carry the haematology, oncology, neurology, metabolic, infectious-disease, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For serotonin-releasing agent (anti-seizure) therapies that require specialised infusion infrastructure, baseline organ-function workup, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For oral, subcutaneous, or in-clinic infusion therapies that can be administered in Saudi Arabia once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule. For therapies that require US-certified treatment center administration (some cell, gene, and complex biologics fall in this bucket), the practical access pathway runs through patient travel to a US-certified treatment center rather than import into Saudi Arabia; the Saudi Arabia tertiary team continues to handle upstream referral package assembly and the long-term follow-up after the patient returns home.
Saudi Arabia pricing reference and payer posture, 2026
Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once the treating physician's documentation is in. The 2026 reference rate used for SAR conversion is 1 USD = 3.750 SAR. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only cost for Fintepla (fenfluramine) reflects the US wholesale acquisition cost published by the manufacturer (UCB Pharma (acquired from Zogenix)) plus standard specialty pharmacy markup; the precise band is delivered in the case quote because it varies by indication, dosing, and pack size.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a complex case the total course cost commonly lands meaningfully above the drug-only band once treatment-centre fees, pre-treatment workup, on-treatment monitoring, complication management, and family logistics are added in.
Payer posture in Saudi Arabia is overwhelmingly cash-pay for named-patient imports and cross-border specialty cases. The relevant public-payer body is CCHI (Council of Cooperative Health Insurance); the portal is at www.cchi.gov.sa. Public coverage generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Fintepla (fenfluramine) case in Saudi Arabia are: (1) Regulatory documentation complexity. The Saudi Food and Drug Authority (SFDA) named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Fintepla (fenfluramine) from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) Clinical eligibility documentation. The treating consultant at the prescribing tertiary centre defines eligibility against the FDA labelled indication and the relevant clinical-practice guideline; Reserve Meds does not adjudicate the clinical decision. (4) Family logistics. Patient and caregiver travel where applicable, accommodation near the treatment center where applicable, in-country transport, translator support where needed, and post-treatment data flow back to the treating Saudi Arabia physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Fintepla (fenfluramine): the labelled indication is seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years and older. The serotonin-releasing agent (anti-seizure) mechanism shapes both the eligibility workup and the monitoring schedule. The relevant clinical-practice guideline body is International League Against Epilepsy (ILAE) developmental and epileptic encephalopathy guidance at www.ilae.org/. The treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Fintepla (fenfluramine) in Saudi Arabia, 2026
The Saudi Food and Drug Authority (SFDA) portal at www.sfda.gov.sa/en and the locally registered medicines list at www.sfda.gov.sa/en/drugs-list are the authoritative source for the current Saudi Arabia listing status of Fintepla (fenfluramine); the snapshot date governs. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages are the authoritative sources for any active Fintepla (fenfluramine) safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication for Fintepla (fenfluramine) remains seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years and older (see the current FDA approval record at accessdata.fda.gov). UCB Pharma (acquired from Zogenix) continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The International League Against Epilepsy (ILAE) developmental and epileptic encephalopathy guidance guidance at www.ilae.org/ remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.